EGRX — Eagle Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual balance sheet for Eagle Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Cash and Short Term Investments	78.8	110	103	97.7	55.3
Net Total Accounts Receivable
Net Total Receivables	66.5	48	51.1	41.1	73.4
Total Inventory
Prepaid Expenses
Total Current Assets	164	179	166	173	189
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	2.4	5.92	2.08	1.64	1.17
Net Goodwill
Net Intangible Assets
Other Long Term Assets
Total Assets	239	255	253	254	406
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	39.7	38.8	38.1	74.4	111
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	77.8	75.4	67.2	77.3	173
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
Other Equity
Total Equity	161	179	186	176	234
Total Liabilities & Shareholders' Equity	239	255	253	254	406
Total Common Shares Outstanding